Stroke Studies

If you think you may qualify for one of these studies, please contact CNI’s Research Department at 303-806-7423.

Inpatient

Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial: To determine whether clopidogrel is effective in preventing major ischemic vascular events in patients receiving aspirin assessed 30 days after TIA/minor stroke.

eligibility and information
Principal Investigator: Ira Chang, MD
Sub-Investigator: Russell Bartt, MD; Chris Fanale, MD; Emily Lampe, MD; Robert Pratt, MD; Byron Spencer, MD; Jeff Wagner, MD

Outpatient

RESPECT: Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral q.d.) in patients with Embolic Stroke of Undetermined Source (RESPECT ESUS). To determine whether Pradaxa, an oral anticoagulant, is superior to aspirin in preventing strokes in patients with Embolic Stroke of Undetermined Source (ESUS).

eligibility and information  
Principal Investigator: Jeffery Wagner, MD

Colorado Neurological Insitute